financetom
Business
financetom
/
Business
/
Waymo to manually test autonomous vehicles at Newark airport
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Waymo to manually test autonomous vehicles at Newark airport
Oct 22, 2025 3:41 PM

Oct 22 (Reuters) - Alphabet's Waymo said on

Wednesday it will begin manual testing of its autonomous

vehicles at Newark Liberty International Airport, as the firm

looks to bring its robotaxis to one of the three main airports

serving the New York City area.

The robotaxi firm has grown slowly but steadily over the

years in the United States despite tough regulations and

expensive technology. Now, it is picking up speed through

partnerships with ride-hailing platforms and fleet operators at

a time when Tesla is rolling out its long-promised

robotaxi service in the country.

Waymo will carry out the testing with human drivers at the

Newark airport in collaboration with the Port Authority of New

York and New Jersey, it said in a post on X.

Commercializing autonomous vehicles has proven difficult in

the U.S. amid setbacks for several companies, including General

Motors' ( GM ) Cruise, due to collisions, recalls and federal

investigations.

Waymo last week said it plans to launch its fully driverless

ride-hailing service in London in 2026, looking to expand its

footprint to major international cities.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Medline Poised to Leverage Business Model to Outsized Performance, RBC Says
Medline Poised to Leverage Business Model to Outsized Performance, RBC Says
Mar 11, 2026
12:48 PM EST, 01/12/2026 (MT Newswires) -- Medline (MDLN) can drive new and existing customers into its supply chain solution partnership model and Medline Branded products, leveraging its vertically integrated business model and macro healthcare tailwinds to deliver outsized performance in the short-to-long term, RBC Capital Markets said. Medline is the only vertically integrated company that develops medical-surgical products at...
Hippocratic AI Consolidates Life Sciences Leadership with Acquisition of Grove AI and Key Executive Appointments
Hippocratic AI Consolidates Life Sciences Leadership with Acquisition of Grove AI and Key Executive Appointments
Mar 11, 2026
The move establishes a dedicated Life Sciences Division and senior executive advisory council to accelerate generative AI across the biopharma and medtech value chain. PALO ALTO, Calif.--(BUSINESS WIRE)-- Hippocratic AI, the global leader and pioneer in patient-facing generative AI healthcare agents, today announced a major expansion of its life sciences business. The company has acquired Grove AI, appointed a President...
Capital One $425 million depositor settlement wins preliminary approval following earlier rejection
Capital One $425 million depositor settlement wins preliminary approval following earlier rejection
Mar 11, 2026
NEW YORK, Jan 12 (Reuters) - A federal judge granted preliminary approval on Monday ‌to Capital One's ​revised $425 million class action ‍settlement with depositors ⁠who ⁠said they were cheated out ‌of ​high interest rates, two months after ⁠rejecting an ‍earlier ​accord, New York Attorney General Letitia James said. U.S. ‍District Judge David Novak in Alexandria, Virginia, ruled after Capital...
Johnson & Johnson Therapy Delivers Strong Results In Colorectal Cancer Trial
Johnson & Johnson Therapy Delivers Strong Results In Colorectal Cancer Trial
Mar 11, 2026
On Saturday, Johnson & Johnson ( JNJ ) shared new longer follow-up results from the Phase 1b/2 OrigAMI-1 study. The trial is evaluating Rybrevant (amivantamab-vmjw) in combination with FOLFOX or FOLFIRI chemotherapy for RAS/BRAF wild-type metastatic colorectal cancer. The company said that encouraging anti-tumor activity, durable responses, and low rates of treatment-related discontinuations observed in this study support further investigation...
Copyright 2023-2026 - www.financetom.com All Rights Reserved